E Fund Management Co. Ltd. Has $57,000 Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

E Fund Management Co. Ltd. reduced its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 57.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,623 shares of the biotechnology company’s stock after selling 18,036 shares during the period. E Fund Management Co. Ltd.’s holdings in Anavex Life Sciences were worth $57,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in Anavex Life Sciences by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company’s stock valued at $22,471,000 after purchasing an additional 54,034 shares during the period. Nwam LLC grew its holdings in shares of Anavex Life Sciences by 4.8% during the first quarter. Nwam LLC now owns 836,730 shares of the biotechnology company’s stock valued at $4,259,000 after buying an additional 38,437 shares in the last quarter. Jupiter Asset Management Ltd. raised its position in Anavex Life Sciences by 675.0% during the first quarter. Jupiter Asset Management Ltd. now owns 804,642 shares of the biotechnology company’s stock valued at $4,096,000 after buying an additional 700,812 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Anavex Life Sciences by 2.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 622,310 shares of the biotechnology company’s stock worth $5,794,000 after acquiring an additional 17,499 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Anavex Life Sciences by 483.8% during the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock worth $1,968,000 after acquiring an additional 386,537 shares during the period. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Trading Up 4.7 %

AVXL opened at $5.76 on Friday. The stock has a fifty day moving average price of $6.00 and a 200 day moving average price of $4.88. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $10.45. The stock has a market cap of $487.54 million, a price-to-earnings ratio of -11.52 and a beta of 0.63.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. During the same period in the previous year, the company earned ($0.14) EPS. As a group, sell-side analysts forecast that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on AVXL shares. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Anavex Life Sciences in a report on Thursday, August 1st. EF Hutton Acquisition Co. I upgraded shares of Anavex Life Sciences to a “strong-buy” rating in a research note on Monday, July 22nd.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.